Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Equity Average: 2016-2025

Historic Equity Average for Intellia Therapeutics (NTLA) over the last 10 years, with Sep 2025 value amounting to $731.8 million.

  • Intellia Therapeutics' Equity Average fell 24.31% to $731.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $731.8 million, marking a year-over-year decrease of 24.31%. This contributed to the annual value of $961.1 million for FY2024, which is 15.91% down from last year.
  • Latest data reveals that Intellia Therapeutics reported Equity Average of $731.8 million as of Q3 2025, which was down 2.11% from $747.6 million recorded in Q2 2025.
  • Over the past 5 years, Intellia Therapeutics' Equity Average peaked at $1.2 billion during Q1 2023, and registered a low of $520.3 million during Q2 2021.
  • Over the past 3 years, Intellia Therapeutics' median Equity Average value was $1.0 billion (recorded in 2024), while the average stood at $973.8 million.
  • Its Equity Average has fluctuated over the past 5 years, first soared by 150.66% in 2021, then decreased by 25.51% in 2025.
  • Quarterly analysis of 5 years shows Intellia Therapeutics' Equity Average stood at $1.1 billion in 2021, then fell by 4.04% to $1.0 billion in 2022, then increased by 1.31% to $1.0 billion in 2023, then decreased by 12.12% to $917.3 million in 2024, then dropped by 24.31% to $731.8 million in 2025.
  • Its Equity Average was $731.8 million in Q3 2025, compared to $747.6 million in Q2 2025 and $825.9 million in Q1 2025.